Bafna Pharmaceuticals Limited

NSE BAFNAPH.NS

Bafna Pharmaceuticals Limited EBT Margin for the year ending March 31, 2024: 4.82%

Bafna Pharmaceuticals Limited EBT Margin is 4.82% for the year ending March 31, 2024, a -52.14% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Bafna Pharmaceuticals Limited EBT Margin for the year ending March 31, 2023 was 10.07%, a 17.33% change year over year.
Bafna Pharmaceuticals Limited EBT Margin for the year ending March 31, 2022 was 8.58%, a 4.91% change year over year.
Bafna Pharmaceuticals Limited EBT Margin for the year ending March 31, 2021 was 8.18%, a 284.50% change year over year.
Bafna Pharmaceuticals Limited EBT Margin for the year ending March 31, 2020 was -4.43%, a 89.49% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NSE: BAFNAPH.NS

Bafna Pharmaceuticals Limited

CEO	Mr. Bansilal Mahaveer Chand Bafna
IPO Date	Nov. 12, 2012
Location	India
Headquarters	Bafna Towers
Employees	363
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Cleaning Supplies Composite Materials Cosmetics Drugstores & Retail Pharmacies Glass Plastics

Description

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India.

Key trends

Past 5 years